Miragen Therapeutics is looking to sell 7 million shares of the company to raise funds for working capital and general corporate purposes.
The Boulder, Colo.-based biopharmaceutical company will price the underwritten public offering at a later date.
Jefferies LLC, Evercore Group LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers of the offering, with Wedbush Securities Inc. and Oppenheimer & Co. Inc. acting as co-lead managers.
The underwriters can buy up to an additional 1,050,000 shares of the company, which is developing treatments for cancer and heart disease.
